Associate Professor Bernadette Fitzgibbon

Bernadette has 20 years of experience in mental health and neuroscience research, specializing in innovative treatments for mental illness and chronic pain, including psychedelic therapies. She has led and overseen numerous clinical trials across universities, hospitals, and private clinics in Australia, as well as collaborated on international trials. Her work includes protocol development, trial delivery, and the implementation of outcomes whilst working alongside with consumers, volunteers, and other stakeholders including government bodies and service providers to translate research outcomes into practice.

Currently, Bernadette serves as the Deputy Director of Research at Monarch Mental Health Group (MMHG) and is a member of the Interventional Psychiatry and Clinical Neuroscience group at the Australian National University. She is an investigator on three investigator-initiated psychedelic clinical trials and one industry-sponsored trial, having overseen more than 100 dosing sessions. Within MMHG, she has contributed to the development of Authorized Prescriber protocols and the implementation of psychedelic-assisted therapy in clinics. In 2023, she completed the Wild Minds “foundations of psychedelic-assisted therapy” training.